TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: Some studies have indicated that response to brentuximab vedotin can occur in patients who have low or undetectable expression of CD30 (< 10%) [94]; this is being assessed in an ongoing phase II trial of brentuximab vedotin plus CHP in patients with PTCL and low CD30 expression (1–10%) [83].